Leerink Partners Research
Advisory Approach
Leerink Partners is the premier healthcare-focused investment bank with three decades of dedicated expertise exclusively serving the healthcare sector. The firm operates with a clear thesis: healthcare companies and investors require specialized knowledge and institutional-quality advisory to navigate one of the world's most complex and regulated industries. Leerink's differentiation lies in combining deep sectoral expertise with uncompromising focus on client value creation across mergers and acquisitions, equity capital markets, and institutional equities.
Founded in 1995, Leerink Partners has established itself as the go-to advisor for healthcare companies of all sizes, from early-stage biotechnology firms to Fortune 500 pharmaceutical giants. The firm's commitment to operational excellence is evident in its leadership team composition—Co-Presidents Tom Davidson and Dan Dubin, M.D. bring combined experience of over 50 years in healthcare investment banking and strategic advisory. Tom Davidson, who joined from PJT Partners, was instrumental in advising on transformational healthcare M&A deals including Amgen's historic $27.3 billion acquisition of Horizon Therapeutics (2022). This proven track record of advising on mega-transactions demonstrates Leerink's credibility and capability to handle deals of any scale.
Sector Focus
Unlike generalist investment banks that dabble in healthcare, Leerink Partners' entire business is healthcare. This exclusive focus spans five core healthcare subsectors:
Biopharma and Life Sciences: The firm partners with biotechnology companies from earliest clinical stages through large-cap pharmaceutical acquisitions. With expertise spanning small molecule drugs, biologics, gene therapies, and advanced therapeutics, Leerink has been involved in numerous significant biopharma transactions. Recent examples include Decibel Therapeutics' sale to Regeneron ($109-213M equity value with clinical milestones) in 2023, where Leerink served as financial advisor. The firm also advised on Q32 Bio's transaction and Neoleukin Therapeutics acquisition, demonstrating active engagement across diverse therapeutic areas.
Healthcare Services: Leerink maintains an active practice serving healthcare providers, payers, and healthcare services companies. Recent engagements include advising Community Health Systems on the sale of Arkansas hospitals ($112M transaction) and providing counsel to major healthcare operators navigating M&A and operational restructuring in an evolving reimbursement landscape.
Medical Technology and Diagnostics: The firm has deep experience with MedTech companies, from early-stage medical device firms to large diversified medtech conglomerates, as well as diagnostic and laboratory services companies.
Digital Health and Health Technology: Leerink is actively engaged with digital health platforms, health information technology, and innovative companies leveraging technology to improve clinical outcomes and reduce costs.
Deal Track Record and M&A Expertise
As of February 2026, Leerink Partners has completed 1,480+ transactions with $75B+ in M&A transaction value and $205B+ in capital raised across all services. The firm's M&A advisory practice has demonstrated sustained excellence, with recent closed transactions including Decibel Therapeutics-Regeneron ($213M potential value), as well as significant healthcare services transactions. The firm's capital markets expertise is evidenced by prominent roles in 2025-2026 equity offerings, including the Evommune IPO (November 2025) and Veradermics IPO (February 2026) where Leerink served as joint book-running manager.
Process and Client Service Model
Leerink Partners' approach centers on hands-on involvement by the most senior bankers, who lead from deal origination through closing. The firm maintains deep relationships with strategic and financial buyers throughout the healthcare ecosystem. Senior management personally engages on significant transactions rather than delegating to junior relationship managers, ensuring sophisticated client counsel on process design, buyer selection, and negotiation strategy.
The firm maintains institutional-quality infrastructure for managing complex healthcare transactions, including rigorous diligence processes tailored to healthcare-specific regulatory, clinical, and commercial dynamics. This operational rigor is essential for healthcare deals, which frequently involve FDA approval pathways, clinical development milestones, partnership dependencies, and sophisticated regulatory approval requirements.
Geographic Presence and Buyer Network
With offices in Boston (headquarters), New York, San Francisco, Charlotte, Nashville, Los Angeles, Miami, and London, Leerink provides comprehensive U.S. and international coverage. The London office expansion reflects the firm's commitment to serving global healthcare companies and accessing international buyer networks.
Leerink's relationships with private equity firms, strategic acquirers, and other capital sources across the healthcare ecosystem represent a significant competitive advantage. The firm's advisory team regularly interfaces with leading life sciences-focused PE firms, major pharmaceutical corporations, and emerging healthcare platforms seeking growth through acquisition.
Competitive Positioning
Leerink differentiates from Goldman Sachs, Morgan Stanley, JPMorgan, and other full-service banks through exclusive focus on healthcare. While larger universal banks offer breadth, Leerink offers depth—every team member's career is dedicated to healthcare. This specialization yields superior outcomes: better understanding of healthcare business models, deeper buyer networks in healthcare-focused firms, and more sophisticated counsel on healthcare-specific strategic issues.
The firm rebuilt independence in 2023 after SVB Financial Group's 2019 acquisition and subsequent collapse in March 2023. Under CEO Jeffrey Leerink's leadership, the management team successfully executed a buyout, restoring the firm's independence and commitment to healthcare exclusively. This event actually strengthened Leerink's competitive positioning, as it reaffirmed the value of specialty investment banking and demonstrated the limitations of housing a healthcare specialist within a diversified banking conglomerate.
Team and Leadership
Leerink is led by healthcare bankers with genuine sector expertise. Founder and CEO Jeffrey A. Leerink established the firm's healthcare-exclusive thesis in 1995 and has never wavered from it. Co-Presidents Tom Davidson and Dan Dubin (M.D.) bring complementary strengths: Davidson's proven M&A deal leadership and Dubin's medical background ensure sophisticated engagement with clinical and scientific complexities underlying healthcare companies.
Key team members include Joseph Gentile (CAO, ex-CFO Lehman Brothers Global Investment Bank), Steven Heineman (General Counsel, former federal prosecutor), Jim Kelly (Director of Research, former Lehman/Credit Suisse equity research), and Robert Leerink (Head of Institutional Equities).
Values and Culture
The firm emphasizes client focus, collaboration, knowledge of healthcare, integrity, respect for diversity, and meritocratic recognition of results. This values framework guides decision-making across M&A advisory, capital markets, and institutional equities.